BioCentury | Jul 10, 2020
Product Development

Evive meets in Phase III for chemotherapy-induced neutropenia; plus regulatory updates for Biogen, Eisai, Merck, AZ

...for Brilinta, Keytruda label extensions FDA granted Priority Review to an sNDA for AstraZeneca’s Brilinta ticagrelor...
...death 1 Sandi Wong, Assistant Editor Benegrastim (F-627) aducanumab (BIIB037) Keytruda, pembrolizumab (MK-3475, lambrolizumab) Lenvima/Keytruda, lenvatinib mesylate/pembrolizumab Brilinta, Brilique, ticagrelor (AZD6140, Possia) Biogen...
BioCentury | Jun 2, 2020
Regulation

June 1 Quick Takes: CHMP recommendations, plus FDA action on AbbVie-Neurocrine, Shionogi, AZ, Lilly, Genentech

...Brilinta approved to prevent first heart attacks, strokes AstraZeneca plc (LSE:AZN; NYSE:AZN) said FDA approved Brilinta...
...approved to prevent first heart attacks, strokes AstraZeneca plc (LSE:AZN; NYSE:AZN) said FDA approved Brilinta ticagrelor...
BioCentury | Apr 26, 2019
Company News

Soriot sees progress in U.S.-China IP debate

...NRDL, AstraZeneca has reached reimbursement agreements with several Chinese provinces. The pharma's cardiovascular drug Brilinta ticagrelor...
...increased 23% to $349 million and Brilinta sales increased 24% to $348 million. Tagrisso and Brilinta...
...exchange rates (CER). Consensus figures provided by FactSet. Elizabeth S. Eaton, Staff Writer Brilinta, Brilique, ticagrelor (AZD6140, Possia) Forxiga...
BioCentury | Mar 1, 2019
Clinical News

Brilinta reduces CV events in patients without prior heart attack, stroke

...AstraZeneca plc (LSE:AZN; NYSE:AZN) said Brilinta ticagrelor met the primary endpoint of reducing major adverse cardiovascular...
...is marketed in the EU as Brilique. AstraZeneca plc (LSE:AZN; NYSE:AZN), London, U.K. Product: Brilinta ticagrelor...
...stroke Status: Phase III data Milestone: Additional Phase III data (2019) Chris Lieu Brilinta, Brilique, ticagrelor (AZD6140, Possia) AstraZeneca...
BioCentury | Feb 25, 2019
Clinical News

Brilinta reduces CV events in patients without prior heart attack, stroke

...AstraZeneca plc (LSE:AZN; NYSE:AZN) said Brilinta ticagrelor met the primary endpoint of reducing major adverse cardiovascular...
...BioCentury that it is premature to speculate about label changes for Brilinta at this time. Brilinta...
...12 (P2RY12; P2Y12) inhibitor is marketed in the EU as Brilique. Chris Lieu Brilinta, Brilique, ticagrelor (AZD6140, Possia) AstraZeneca...
BioCentury | Feb 1, 2019
Company News

AZ, UPMC in value-based agreement for Brilinta

...patients, AstraZeneca plc (LSE:AZN; NYSE:AZN) signed a value-based contract with UPMC Health Plan for Brilinta ticagrelor...
...label, Brilinta is superior to Plavix for at least the first 12 months following ACS. Brilinta...
...London, U.K. University of Pittsburgh Medical Center, Pittsburgh, Pa. Business: Cardiovascular Chris Lieu Brilinta, Brilique, ticagrelor (AZD6140, Possia) AstraZeneca...
BioCentury | Jan 28, 2019
Company News

AZ, UPMC in value-based agreement for Brilinta

...patients, AstraZeneca plc (LSE:AZN; NYSE:AZN) signed a value-based contract with UPMC Health Plan for Brilinta ticagrelor...
...label, Brilinta is superior to Plavix for at least the first 12 months following ACS. Brilinta...
...of data about how their drugs work in the real-world setting. Chris Lieu Brilinta, Brilique, ticagrelor (AZD6140, Possia) AstraZeneca...
BioCentury | Nov 9, 2018
Company News

AZ looks to new medicines to drive growth

...obstructive pulmonary disease (COPD) drug Bevespi Aerosphere glycopyrronium/formoterol and acute coronary syndrome (ACS) drug Brilinta ticagrelor...
...by FactSet. AstraZeneca plc (LSE:AZN; NYSE:AZN), London, U.K. Business: Pharmaceuticals Jaime De Leon Brilinta, Brilique, ticagrelor (AZD6140, Possia) Fasenra...
BioCentury | Nov 8, 2018
Company News

AZ looks to new medicines to drive growth

...obstructive pulmonary disease (COPD) drug Bevespi Aerosphere glycopyrronium/formoterol and acute coronary syndrome (ACS) drug Brilinta ticagrelor...
...the consensus estimate of $0.70. Consensus figures provided by FactSet. Jaime De Leon Brilinta, Brilique, ticagrelor (AZD6140, Possia) Fasenra...
BioCentury | Oct 19, 2018
Financial News

PhaseBio, Osmotica price NASDAQ IPOs well below range

...reversal agent for antiplatelet therapy ticagrelor. It is a Fab antibody fragment that binds to ticagrelor...
Items per page:
1 - 10 of 145